Exhibit 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

	2013															2012															% Change
	1Q			2Q			3Q			4Q			Full Year			1Q			2Q			3Q			4Q			Full Year			4Q		Full Year
	.
Sales	$	10,671		$	11,010		$	11,032		$	11,319		$	44,033		$	11,731		$	12,311		$	11,488		$	11,738		$	47,267		-4	%	-7	%
Costs, Expenses and Other
Materials and production	3,959			4,284			4,104			4,607			16,954			4,037			4,112			4,137			4,160			16,446			11	%	3	%
Marketing and administrative	2,987			3,140			2,803			2,982			11,911			3,074			3,249			3,063			3,390			12,776			-12	%	-7	%
Research and development	1,907			2,101			1,660			1,836			7,503			1,862			2,165			1,918			2,224			8,168			-17	%	-8	%
Restructuring costs	119			155			870			565			1,709			219			144			110			191			664			*		*
Equity income from affiliates	(133		)	(116		)	(102		)	(53		)	(404		)	(110		)	(142		)	(158		)	(231		)	(642		)	-77	%	-37	%
Other (income) expense, net	282			201			172			157			815			142			103			200			669			1,116			-77	%	-27	%
Income Before Taxes	1,550			1,245			1,525			1,225			5,545			2,507			2,680			2,218			1,335			8,739			-8	%	-37	%
Income Tax (Benefit) Provision	(66		)	310			375			410			1,028			740			860			455			385			2,440
Net Income	1,616			935			1,150			815			4,517			1,767			1,820			1,763			950			6,299			-14	%	-28	%
Less: Net Income Attributable to Noncontrolling Interests	23			29			26			34			113			29			27			34			42			131
Net Income Attributable to Merck & Co., Inc.	$	1,593		$	906		$	1,124		$	781		$	4,404		$	1,738		$	1,793		$	1,729		$	908		$	6,168		-14	%	-29	%
Earnings per Common Share Assuming Dilution	$	0.52		$	0.30		$	0.38		$	0.26		$	1.47		$	0.56		$	0.58		$	0.56		$	0.30		$	2.00		-13	%	-27	%
Average Shares Outstanding Assuming Dilution	3,053			3,010			2,960			2,959			2,996			3,074			3,072			3,079			3,074			3,076
Tax Rate	-4.3		%	24.9		%	24.6		%	33.5		%	18.5		%	29.5		%	32.1		%	20.5		%	28.8		%	27.9		%

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FOURTH QUARTER 2012

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2c

	GAAP			Acquisition- Related Costs (1)		Restructuring Costs (2)		Certain Other Items (3)		Adjustment Subtotal			Non-GAAP
Sales	$	11,738											$	11,738
Costs, Expenses and Other
Materials and production	4,160			1,185		40				1,225			2,935
Marketing and administrative	3,390			89		20				109			3,281
Research and development	2,224			24		3				27			2,197
Restructuring costs	191					191				191			—
Equity income from affiliates	(231		)							—			(231		)
Other (income) expense, net	669							493		493			176
Income Before Taxes	1,335			(1,298	)	(254	)	(493	)	(2,045		)	3,380
Taxes on Income	385									(413		)(4)	798
Net Income	950									(1,632		)	2,582
Less: Net Income Attributable to Noncontrolling Interests	42									—			42
Net Income Attributable to Merck & Co., Inc.	$	908								$	(1,632	)	$	2,540
Earnings per Common Share Assuming Dilution	$	0.30											$	0.83
Average Shares Outstanding Assuming Dilution	3,074												3,074
Tax Rate	28.8		%										23.6		%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions.  Amounts included in marketing and administrative expenses reflect merger integration costs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

(3) Represents a net charge related to the settlement of certain shareholder litigation.

(4) Represents the estimated tax impact on the reconciling items.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FULL YEAR 2012

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2d

	GAAP			Acquisition- Related Costs (1)		Restructuring Costs (2)		Certain Other Items (3)		Adjustment Subtotal			Non-GAAP
Sales	$	47,267											$	47,267
Costs, Expenses and Other
Materials and production	16,446			4,872		188				5,060			11,386
Marketing and administrative	12,776			272		90				362			12,414
Research and development	8,168			200		57				257			7,911
Restructuring costs	664					664				664			—
Equity income from affiliates	(642		)							—			(642		)
Other (income) expense, net	1,116							493		493			623
Income Before Taxes	8,739			(5,344	)	(999	)	(493	)	(6,836		)	15,575
Taxes on Income	2,440									(1,261		)(4)	3,701
Net Income	6,299									(5,575		)	11,874
Less: Net Income Attributable to Noncontrolling Interests	131									—			131
Net Income Attributable to Merck & Co., Inc.	$	6,168								$	(5,575	)	$	11,743
Earnings per Common Share Assuming Dilution	$	2.00											$	3.82
Average Shares Outstanding Assuming Dilution	3,076												3,076
Tax Rate	27.9		%										23.8		%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1)  Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions.  Amounts included in marketing and administrative expenses reflect merger integration costs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

(3) Represents a net charge related to the settlement of certain shareholder litigation.

(4) Represents the estimated tax impact on the reconciling items.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES 

FOURTH QUARTER 2013

(AMOUNTS IN MILLIONS)

Table 3a

	Global					U.S.					International
	4Q13		4Q12		% Change	4Q13		4Q12		% Change	4Q13			4Q12		% Change
TOTAL SALES (1)	$	11,319	$	11,738	-4	$	4,519	$	4,716	-4	$	6,800		$	7,022	-3
PHARMACEUTICAL	9,760		10,085		-3	3,761		3,915		-4	5,999			6,170		-3
Primary Care and Women’s Health
Cardiovascular
Zetia	716		676		6	400		345		16	317			331		-4
Vytorin	436		435			182		186		-2	253			249		2
Diabetes & Obesity
Januvia	1,121		1,134		-1	552		565		-2	569			568
Janumet	503		452		11	228		237		-4	275			215		28
Respiratory
Nasonex	327		308		6	174		138		26	153			169		-10
Singulair	298		480		-38	16		25		-35	282			456		-38
Dulera	95		67		42	91		64		40	5			2		98
Asmanex	51		44		17	45		38		17	6			5		14
Women’s Health & Endocrine
NuvaRing	193		164		17	123		99		24	70			66		7
Fosamax	139		154		-10	4		6		-29	135			148		-9
Implanon	120		94		28	62		35		78	59			59		-1
Follistim AQ	101		116		-13	23		42		-45	78			75		4
Cerazette	50		68		-28						50			68		-28
Other
Arcoxia	131		115		13						131			115		13
Avelox	37		55		-32	35		52		-32	2			3		-34
Hospital and Specialty
Immunology
Remicade	620		549		13						620			549		13
Simponi	146		95		53						146			95		53
Infectious Disease
Isentress	442		381		16	249		214		16	192			167		15
Cancidas	183		145		26	9		9		-4	175			136		28
Invanz	128		116		10	66		61		8	62			55		12
PegIntron	124		143		-13	11		8		32	113			134		-16
Noxafil	98		68		44	43		20		*	55			47		15
Victrelis	81		115		-29	25		52		-53	57			63		-10
Oncology
Emend	134		131		2	80		74		7	54			57		-6
Temodar	111		229		-51	17		101		-83	95			128		-26
Other
Cosopt / Trusopt	103		113		-9	3		3		-10	100			110		-9
Bridion	82		75		10						82			75		10
Integrilin	46		51		-9	42		46		-9	4			5		-13
Diversified Brands
Cozaar / Hyzaar	246		315		-22	9		12		-28	237			303		-22
Primaxin	79		83		-5	3		4		-22	76			80		-4
Zocor	79		98		-19	7		7		-8	73			90		-20
Propecia	77		112		-31	6		29		-79	70			83		-15
Remeron	56		57		-1	3		1		*	54			56		-4
Clarinex	55		56		-1	5		4		35	50			52		-3
Claritin Rx	52		63		-16						52			63		-16
Proscar	48		56		-15	1		2		-40	47			54		-14
Maxalt	25		162		-85	1		128		-99	24			34		-30
Vaccines
Gardasil	394		442		-11	248		304		-19	146			138		6
ProQuad, M-M-R II and Varivax	273		306		-11	238		283		-16	35			22		55
Zostavax	264		225		18	210		211		-1	54			14		*
Pneumovax 23	241		208		16	176		165		7	65			43		52
RotaTeq	129		168		-23	88		136		-35	41			32		27
Other Pharmaceutical (2)	1,126		1,161		-3	286		209		37	838			952		-12
ANIMAL HEALTH	871		898		-3	198		236		-16	673			662		2
CONSUMER CARE	390		395		-1	254		250		1	137			145		-6
Claritin OTC	92		100		-8	66		68		-3	26			32		-20
Other Revenues (3)	298		360		-17	307		315		-2	(9		)	45		*
Astra	193		251		-23	193		251		-23

* 100% or greater

(1)  Only select products are shown.

(2)  Includes Pharmaceutical products not individually shown above.  Other Vaccines sales included in Other Pharmaceutical were $101 million and $69 million on a global basis for fourth quarter 2013 and 2012, respectively.

(3)  Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales.   In addition, Other revenues in the fourth quarter of 2013 reflect $50 million of revenue for the out-license of a pipeline compound. 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES 

FULL YEAR 2013

(AMOUNTS IN MILLIONS)

Table 3b

	Global					U.S.					International
	Full Year 2013		Full Year 2012		% Change	Full Year 2013		Full Year 2012		% Change	Full Year 2013		Full Year 2012		% Change
TOTAL SALES (1)	$	44,033	$	47,267	-7	$	18,246	$	20,392	-11	$	25,787	$	26,875	-4
PHARMACEUTICAL	37,437		40,601		-8	14,854		17,041		-13	22,582		23,560		-4
Primary Care and Women’s Health
Cardiovascular
Zetia	2,658		2,567		4	1,454		1,332		9	1,204		1,235		-3
Vytorin	1,643		1,747		-6	673		764		-12	970		983		-1
Diabetes & Obesity
Januvia	4,004		4,086		-2	2,068		2,136		-3	1,935		1,950		-1
Janumet	1,829		1,659		10	878		865		2	951		795		20
Respiratory
Nasonex	1,335		1,268		5	681		597		14	654		671		-2
Singulair	1,196		3,853		-69	61		2,152		-97	1,135		1,701		-33
Dulera	324		207		56	309		199		55	15		8		93
Asmanex	184		185		-1	162		166		-2	22		19		16
Women’s Health & Endocrine
NuvaRing	686		623		10	426		366		16	260		257		1
Fosamax	560		676		-17	20		28		-28	540		648		-17
Follistim AQ	481		468		3	181		165		9	300		303		-1
Implanon	403		348		16	205		139		48	197		209		-6
Cerazette	208		271		-23						208		271		-23
Other
Arcoxia	484		453		7						484		453		7
Avelox	140		201		-31	130		192		-32	10		9		2
Hospital and Specialty
Immunology
Remicade	2,271		2,076		9						2,271		2,076		9
Simponi	500		331		51						500		331		51
Infectious Disease
Isentress	1,643		1,515		8	882		822		7	761		692		10
Cancidas	660		619		7	31		32		-3	630		587		7
PegIntron	496		653		-24	43		87		-51	453		565		-20
Invanz	488		445		10	252		227		11	236		218		8
Victrelis	428		502		-15	158		267		-41	270		234		15
Noxafil	309		258		20	106		75		42	203		184		11
Oncology
Temodar	708		917		-23	304		423		-28	404		494		-18
Emend	507		489		4	293		276		6	214		213
Other
Cosopt / Trusopt	416		444		-6	16		14		22	400		430		-7
Bridion	288		261		10						288		261		10
Integrilin	186		211		-12	170		193		-12	17		18		-8
Diversified Brands
Cozaar / Hyzaar	1,006		1,284		-22	35		28		24	971		1,256		-23
Primaxin	335		384		-13	18		21		-13	317		363		-13
Zocor	301		383		-21	24		27		-10	276		356		-22
Propecia	283		424		-33	25		124		-80	258		300		-14
Clarinex	235		393		-40	19		126		-85	216		267		-19
Claritin Rx	204		244		-16						204		244		-16
Remeron	206		232		-11	6		5		28	200		227		-12
Proscar	183		217		-15	4		5		-8	179		212		-15
Maxalt	149		638		-77	38		491		-92	111		146		-24
Vaccines
Gardasil	1,831		1,631		12	1,295		1,113		16	536		517		4
ProQuad, M-M-R II and Varivax	1,306		1,273		3	1,172		1,164		1	134		109		23
Zostavax	758		651		16	653		607		8	105		44		*
Pneumovax 23	653		580		13	491		461		6	162		118		37
RotaTeq	636		601		6	471		453		4	166		148		12
Other Pharmaceutical (2)	4,316		4,333			1,100		899		22	3,215		3,436		-6
ANIMAL HEALTH	3,362		3,399		-1	856		879		-3	2,506		2,520		-1
CONSUMER CARE (3)	1,894		1,952		-3	1,326		1,306		2	568		646		-12
Claritin OTC	471		532		-12	410		386		6	61		147		-58
Other Revenues (4)	1,340		1,315		2	1,209		1,166		4	131		149		-12
Astra	920		915		1	920		915		1

* 100% or greater

(1)  Only select products are shown.

(2)  Includes Pharmaceutical products not individually shown above.  Other Vaccines sales included in Other Pharmaceutical were $368 million and $319 million on a global basis for full year 2013 and 2012, respectively.

(3)  The decrease in Consumer Care sales in the full year of 2013 resulted from the ongoing termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

(4) Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales.   In addition, Other revenues in the full year of 2013 reflect $50 million of revenue for the out-license of a pipeline compound.

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3c

	1Q13			2Q13			3Q13			4Q13			Full Year			1Q12			2Q12			3Q12			4Q12			Full Year			% Change 4Q	% Change Full Year
TOTAL PHARMACEUTICAL	$	8,891		$	9,310		$	9,475		$	9,760		$	37,437		$	10,082		$	10,560		$	9,875		$	10,085		$	40,601		-3	-8
United States	3,256			3,689			4,148			3,761			14,854			4,189			4,633			4,304			3,915			17,041			-4	-13
% Pharmaceutical Sales	36.6		%	39.6		%	43.8		%	38.5		%	39.7		%	41.6		%	43.9		%	43.6		%	38.8		%	42.0		%
Europe (1)	2,465			2,343			2,276			2,535			9,619			2,558			2,540			2,210			2,441			9,750			4	-1
% Pharmaceutical Sales	27.7		%	25.2		%	24.0		%	26.0		%	25.7		%	25.4		%	24.1		%	22.4		%	24.2		%	24.0		%
Japan	1,034			948			893			1,074			3,949			1,267			1,199			1,124			1,388			4,978			-23	-21
% Pharmaceutical Sales	11.6		%	10.2		%	9.4		%	11.0		%	10.5		%	12.6		%	11.4		%	11.4		%	13.8		%	12.3		%
Latin America	596			676			628			667			2,567			627			668			715			742			2,752			-10	-7
% Pharmaceutical Sales	6.7		%	7.3		%	6.6		%	6.8		%	6.9		%	6.2		%	6.3		%	7.2		%	7.4		%	6.8		%
Asia Pacific	822			874			799			870			3,365			762			787			846			864			3,259			1	3
% Pharmaceutical Sales	9.2		%	9.4		%	8.4		%	8.9		%	9.0		%	7.6		%	7.4		%	8.6		%	8.6		%	8.0		%
China	271			297			242			293			1,103			221			262			262			298			1,044			-2	6
Eastern Europe/Middle East Africa	439			479			431			534			1,883			361			441			366			416			1,584			29	19
% Pharmaceutical Sales	4.9		%	5.1		%	4.5		%	5.5		%	5.0		%	3.6		%	4.2		%	3.7		%	4.1		%	3.9		%
Canada	245			257			253			276			1,030			264			236			257			276			1,034			0	0
% Pharmaceutical Sales	2.8		%	2.8		%	2.7		%	2.8		%	2.8		%	2.6		%	2.2		%	2.6		%	2.7		%	2.5		%
Other	34			45			47			43			170			53			56			52			42			203			2	-16
% Pharmaceutical Sales	0.4		%	0.5		%	0.5		%	0.4		%	0.5		%	0.5		%	0.5		%	0.5		%	0.4		%	0.5		%

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.

FOURTH QUARTER 2013

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE, NET - GAAP

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 4

EQUITY INCOME FROM AFFILIATES

	4Q13		4Q12			Full Year 2013		Full Year 2012
ASTRAZENECA LP	$	50	$	233		$	352	$	621
Other (1)	3		(2		)	52		21
TOTAL	$	53	$	231		$	404	$	642

(1) Includes results for Sanofi Pasteur MSD.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a “NET” basis.

	4Q13		4Q12		Full Year 2013		Full Year 2012
GARDASIL	$	70	$	67	$	291	$	264
FLU VACCINES	69		79		162		161
OTHER VIRAL VACCINES	25		26		104		107
ZOSTAVAX	27		—		68		—
ROTATEQ	14		12		55		47
HEPATITIS VACCINES	8		7		31		31
Other Vaccines	122		122		453		474
TOTAL SANOFI PASTEUR MSD SALES	$	335	$	313	$	1,164	$	1,084

OTHER (INCOME) EXPENSE, NET

	4Q13			4Q12			Full Year 2013			Full Year 2012
INTEREST INCOME	$	(75	)	$	(55	)	$	(264	)	$	(232	)
INTEREST EXPENSE	201			190			801			714
EXCHANGE LOSSES	12			55			290			185
Other, net (1)	19			479			(12		)	449
TOTAL	$	157		$	669		$	815		$	1,116

(1) Other, net for the fourth quarter and full year of 2012 includes a $493 million net charge related to the settlement of certain shareholder litigation.